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period followed by a 10-week, randomized, double-blind,
placebo-controlled period. A total of 170 patients were random-
ized to receive a physician-determined dose of botulinium toxin
type A (BoNT-A) or placebo. Functional disability was measured
by patients and physicians using a scale from 0 (no functional
disability) to 4 (very severe disability). Functional disability was
measured at study visits at weeks 2, 4, 6, 8, and 10 of the
randomized, double-blind period of the study. RESULTS: The
baseline mean physician-assessed functional disability scores
were 1.87 for botulinium toxin and 1.88 for placebo. The mean
change in physician-assessed functional disability showed a
greater reduction in the BoNT-A group compared with the
placebo group at all timepoints, with the difference being signiﬁ-
cant at weeks 4, 6, and 8 (P  0.029). A higher proportion of
patients had a decrease of one grade or more in physician-
assessed functional disability in the BoNT-A group at all time
periods. The baseline mean patient-assessed functional disability
scores were 1.95 in the BoNT-A group and 1.78 in the placebo
group. A greater reduction in the mean change of patient-
assessed functional disability was seen with BoNT-A compared
with placebo at all timepoints. The patient-assessed functional
disability between the two groups was signiﬁcantly different at
weeks 2, 6, 8, and 10 (P  0.008). A one grade or greater
reduction in patient-assessed functional disability was experi-
enced by a higher proportion of botulinium toxin patients at all
timepoints compared with placebo. Rates of adverse events were
nearly equivalent between groups (59.1% BoNT-A vs. 58.5%
placebo group). CONCLUSION: Treatment with BoNT-A
showed signiﬁcant and sustained improvements in functional
disability when assessed by both the physician and the patient.
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OBJECTIVE: Most Multiple Sclerosis (MS) clinical trials focus
on relapses and MRI measures of disease activity. Disease
outcome measures in clinical trials and practice focus on physical
outcomes and, in particular, the ambulation oriented Expanded
Disability Severity Scale (EDSS). This study evaluated the rela-
tionships between various physical and patient reported out-
comes (PROs) in MS patients. METHODS: Charts were
abstracted for 98 MS patients in a single MS center that captured
both physician-evaluated outcomes and PROs. This study
reports the last available evaluation. Spearman rank correlations
and a recursive partitioning algorithm were used to evaluate
relationships between ﬁve physical (box/blocks, 9-hole peg,
timed walk, Tinetti balance, and EDSS) and 3 PRO (modiﬁed
fatigue impact scale, Beck depression inventory, and Espworth
sleepiness scale) measures in addition to standard demographic
and disease characterizing variables. RESULTS: The rank corre-
lation between the box/blocks and nine-hole peg tests (standard
tests for ﬁne motor control) was 0.9 (p < 0.001) while the rank
correlation between box/blocks and timed walk was 0.71
(p < 0.001). Moderate correlations were observed for the PROs:
fatigue and depression was 0.57 (p < 0.001); fatigue and sleepi-
ness was 0.52 (p < 0.001); and depression and sleepiness was
0.39 (p < 0.001). No signiﬁcant correlations were observed
between either depression or sleepiness and any physical
outcome measure. Fatigue was correlated with 9-hole peg (0.41,
p = 0.023), timed walk (0.44, p = 0.014), and EDSS (0.34,
p = 0.013). The recursive partitioning algorithm found the stron-
gest physical outcome associated with fatigue to be EDSS and the
best split was at EDSS <= (“minimal” versus “mild” disability).
CONCLUSION: Moderate correlations were found within the
physical outcome measures and within PROs; but the relation-
ship between physical outcomes and PROs was weak. Because
most clinical trials and evaluating neurologists focus on physical
measures in MS, it is likely that much of the disease impact is
being missed.
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OBJECTIVE: To evaluate investigator and patient-reported sat-
isfaction and ease-of-use of Azilect(r) (rasagiline tablets) in com-
munity neurological practices. Rasagiline is a potent, once daily,
novel, irreversible MAO-B inhibitor approved for PD as initial
monotherapy or adjunct therapy. Pivotal trials showed improve-
ment in the Uniﬁed Parkinson’s Disease Rating Scale for mono-
therapy and reduced OFF time for adjunct therapy. Other
measures of patient- and investigator-reported outcomes may
be important such as ease-of-use and patient satisfaction.
METHODS: LEGATO is an open-label study of once-daily rasa-
giline 0.5 mg and 1 mg in PD patients at 38 community-based
centers. Baseline treatment determined patients’ stratiﬁcation to
adjunct or monotherapy. Evaluations were at weeks 1, 2, 4, and
12. Endpoints included: patient and investigator reported Clini-
cal Global Improvement(CGI) score; investigator-and patient-
reported change from baseline in Schwab & England Activities
of Daily (ADL) score; and investigator-and patient-reported
satisfaction/ease-of-use ratings. RESULTS: A total of 272
patients were enrolled: 123 monotherapy patients and 149
adjunct patients with 245 completers. At all visits, investigator
reported CGI was signiﬁcantly improved for both mono and
adjunct therapy (p < 0.001). At all visits, patient reported CGI
was also signiﬁcantly improved for both mono and adjunct
therapy (p < 0.001). Patient-reported CGI was similar to Inves-
tigators’, although maximal improvement occurred later for
patients. Median satisfaction/ease-of-use scores were 9 for mono-
therapy (range 6 to 30 with 6 being best) and 10 for adjunct
therapy (range of 8 to 40 with 8 being best) for both patients
and investigators. Investigators noted statistically signiﬁcant
improvement in ADL of 3 points at the end of 12 weeks, whereas
patients did not note changes from baseline. CONCLUSION:
Both investigators and patients noted signiﬁcant effectiveness
beginning at week one as measured by CGI, found rasagiline
convenient and easy to use, and were satisﬁed with the dosing
frequency and tolerability of once-daily rasagiline.
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OBJECTIVE: The purpose of this study was to develop an instru-
ment to assess treatment satisfaction for patients with insomnia.
METHODS: Speciﬁc patient satisfaction items were identiﬁed
from the existing literature by an expert panel of physicians,
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researchers, and clinicians. Two focus groups containing eight to
ten patients who met the inclusion criteria for insomnia (diagno-
sis, history) were surveyed. A preliminary instrument containing
42 items (scale: 1 = not important at all to 5 = extremely impor-
tant), including demographic characteristics and co-morbidities,
was developed and then pretested in 14 additional patients prior
to validation testing. RESULTS: Currently, 109 patients have
participated in the testing of the instrument (mean age 50 + 11.5
years, 67.9% female). Principal components exploratory factor
analysis (KMO = 0.85) reduced the instrument to 17 items
(Cronbach á = 0.90) in 5 domains. Cronbach á for the 5 domains
(contentment, dosing ﬂexibility, outlook, value, and treatment
satisfaction) ranged from 0.73 to 0.86. Convergent and discrimi-
nant validity were assessed to determine scale acceptability for
further analysis. Goodness of ﬁt measures for the measurement
model (AMOS, version 7) were c2 = 50.8, df = 53, p = 0.559;
CFI = 1.00, GFI = 0.94, NFI = 0.92, RMSEA = 0.001, which
support the relationship between the data and the hypothesized
model. We anticipate recruiting more patients to ensure that the
data are consistent. CONCLUSION: Preliminary data from the
structural equation model revealed a 17-item instrument with 5
important domains (contentment with therapy, dosing ﬂexibility,
and outlook with respect to treatment satisfaction and value).
Further assessment and validation of the instrument is planned.
This novel instrument may provide greater knowledge regarding
the impact of psychological domains on treatment satisfaction
for patients with insomnia.
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OBJECTIVE: Multiple sclerosis (MS) is a chronic neurodegen-
erative disease which is the second most frequent cause of neu-
rological disability in young adults. The relapsing forms of the
disease are primarily treated with interferon beta or glatiramer
acetate. The aim of this study was to evaluate the level of satis-
faction of Spanish MS patients treated with the new formula-
tion of Avonex®, and whether this inﬂuences adherence.
METHODS: Data were obtained from the Global Adherence
Project, a multicenter open-label, post-marketing surveillance
study, performed in 17 centers in Spain. This included assessment
of the level of patient and neurologist satisfaction with the new
Avonex® formulation after 6 months of therapy. Two question-
naires were administered, one for patients and another for neu-
rologists. The study was approved by ethics committees and
patients signed informed consent. Descriptive statistical analyses
were performed. RESULTS: Of 257 patients included, 57
(22.2%) were treated with Avonex®; 55.4% of patients and
5.9% of neurologists were fully satisﬁed with the new formula-
tion. Most neurologists (88.3%) had intermediate satisfaction
scores. For patients and for neurologists, the most noteworthy
aspect of the change of formulation was the ease of use (73.2%
and 82.4%, respectively), followed by ease of storage (44.6%
and 29.4%), ease of injection (39.3% and 70.6%), less medica-
tion administered (25.0% and 11.8%) and for patients only,
better tolerability (8.9%). Adherence with Avonex® was 96.4%,
the highest among the therapies evaluated. CONCLUSION:
Both patients and neurologists were satisﬁed with Avonex® as
solution for injection. The most noteworthy aspect was the ease
of use. This seems to have a positive inﬂuence in the overall
patients’ adherence to the therapy.
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OBJECTIVE: Assess the types and number of health care pro-
fessionals seen by patients before diagnosis with dystonia and the
length of time from onset of symptoms. Describe the common
types of dystonias that are treated by the movement disorder
specialists and when appropriate, receive Botulinum Toxin Type
A treatment. METHODS: Patients with dystonia were asked to
complete a 19-question survey developed by the Canadian Move-
ment Disorders Survey Group. Questions included patient demo-
graphics, length of time from onset, number and types of
physicians seen, other diagnoses made, number treated with
Botulinum Toxin Type A and distance traveled. RESULTS: In this
interim analysis, 550 patients with dystonia were surveyed.
Majority of the patients were female (71%), traveling an average
of 99 km one-way. Most common dystonia diagnoses were
cervical dystonia (51%), hemifacial spasm (20%), and ble-
pharospasm (11%). Common diagnoses made prior to the dys-
tonia diagnoses were nerve/muscle problem (34%), stress/
psychological problem (39%), tremor (20%), ﬁbromyalgia
(19%), TMJ (16%), joint/tendon problem (15%) and spine
(11%). The average number of physicians seen before the dysto-
nia diagnosis was 3.2. Amongst these were family physician
(78%), neurologist (78%), movement disorder specialist (29%),
chiropractor (18%), eye care doctor (17%), neurosurgeon
(11%), and physiotherapist (15%). Most physicians who made
the dystonia diagnosis were neurologist (69%) and movement
disorder specialist (27%). The average time in years from onset
of symptoms to dystonia diagnosis were: cervical dystonia 5.2
(n = 278), blepharospasm 3.5 (n = 60), spasmodic dysphonia
4.0 (n = 10), limb dystonia 1.2 (n = 17), Meige syndrome 2.6
(n = 14), hemifacial spasm 3.2 (n = 112), generalized dystonia
8.0 (n = 8), oromandibular dystonia 5.0 (n = 8). 94% of patients
were treated with Botulinum Toxin Type A following their diag-
nosis with dystonia. CONCLUSION: The number of physicians
seen and length of time from onset to dystonia diagnosis is
substantial. Increased awareness of dystonia at the primary care
level may improve these rates.
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OBJECTIVE: Highly expensive disease modifying agents
(DMAs) were introduced in the 1990s to reduce the frequency of
relapse and to slow disease progression in patients with multiple
sclerosis (MS). However, the patterns of DMAs use remain
largely unknown. This study examines data from 2001–2005
population-based survey of MS patients to estimate duration of
DMA use and switching behavior, controlling for patient risk
factors. METHODS: We examined patterns of DMA use of 670
patients with relapsing remitting (RR) and secondary progressive
(SP) MS from the Sonya Slifka Longitudinal Multiple Sclerosis
Study. We generated Kaplan Meier covariate-adjusted estimates
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